ProviderConnect™
An enterprise solution that saves lives
CONNECT YOUR EHR
Get every vital you need
RED FLAG DAYS
If a patient's vitals go beyond your set range, you get an alert
IMPROVED OUTCOMES
For patients, caregivers, and clinical teams
The Care Gap
- 90 days between cancer appointments
- 15 minutes with your doctor per visit
- 9 out of 10 health apps don't support your patient's language
Treatment Decisions Based on Memory
You ask "How have you been?" and make critical treatment decisions based on what patients remember from 90+ days. No continuous vitals. No side effect trends. No medication adherence data. Just hope they're telling you everything.
The Invisible Patient
Between appointments, you have zero visibility. Medication adherence? Unknown. Pain levels increasing? You'll find out at the next visit-if they make it. Symptoms escalating? The ER call will be your first warning.
Care Coordination Chaos
Multiple specialists treating one patient with no shared visibility. Oncology doesn't see cardiology notes. Psychiatrists don't see cancer vitals. The patient becomes their own (unreliable) medical record coordinator.
The Solution
CareHub™ ProviderConnect™ gives you continuous visibility into what happens between appointments. Patients track daily: medication adherence, pain levels, symptoms, PHQ-9 scores, vitals. You see 60-90 data points per month instead of one snapshot per quarter.
Result: Proactive intervention before symptoms become crises. Evidence-based decisions instead of educated guesses. Real-time alerts when patients miss medications or report concerning symptoms.
Value Propositions by Stakeholder
CareHub™ creates value for every participant in the care ecosystem. Each stakeholder benefits in distinct ways from continuous patient tracking.
For Patients
Life-changing. Potentially life-saving. Patients with chronic disease are desperate for tools that help them fight back. CareHub™ gives them that power.
- Earlier intervention = better outcomes (catching symptom escalation before crisis)
- Improved medication adherence linked to 15-25% better survival rates in chronic disease
- Reduced anxiety from knowing their care team sees their daily reality
- Single source of truth for medications, symptoms, and appointments
- Shared calendar with family caregivers for coordinated care
- Historical data that travels with them across providers
The stakes are real: For cancer patients, early symptom detection can mean the difference between outpatient treatment and emergency hospitalization. For diabetes patients, continuous tracking prevents the slow slide toward amputation and blindness.
For Family Caregivers (The Multiplier)
Every patient comes with a care network: Spouses, adult children, and family members managing complex care schedules multiply the platform's impact.
- Shared visibility into treatment schedules and medication adherence
- Coordinated care responsibilities (who's driving to chemo? who's managing meds?)
- Reduced caregiver burnout through better organization
- Direct communication channel to care team without playing phone tag
Note: Family caregivers are included in patient subscriptions and not double-counted as separate users.
For Solo Practitioners
The efficiency play: Independent physicians and small practices gain enterprise-level patient monitoring without enterprise-level costs or complexity.
- Pre-populated appointment summaries (patient-tracked data ready before visit)
- Reduced phone calls and portal messages ("How is the new medication working?")
- Early warning alerts that prevent after-hours crises
- Simple integration with no IT department required
- Competitive differentiation vs. larger practices
For Clinics & Hospital Systems
The outcomes play: Integrated delivery networks and specialty clinics gain measurable improvements in care quality metrics.
- 20-30% reduction in urgent care visits and ER utilization
- 15-25% improvement in medication adherence rates
- Better HEDIS/quality scores for value-based care contracts
- Reduced readmission penalties (CMS 30-day readmission measures)
- Care coordination across multiple specialists treating same patient
- Population health insights across chronic disease cohorts
For Pharmaceutical Companies
The data play: Pharma gains access to real-world evidence that clinical trials cannot capture.
- Continuous patient-reported outcomes
- Longitudinal symptom tracking across months/years
- Real-world adherence patterns and side effect profiles
- Comorbidity insights for drug interaction research
- Post-market surveillance data for FDA compliance
For Investors (Founders, Token Holders, Patients)
Philanthropic capitalism with venture returns: CareHub offers the rare opportunity to generate market-rate financial returns while solving a $470B unpaid caregiving crisis.
Financial Projections:
- Base-case 2030 planning scenario: aligns with the current Value Proposition at approximately $830M+ ARR across hospital EHR, pharma RWE, and solo practitioner revenue streams.
- Illustrative long-term valuation framework: at a 10x ARR multiple, that base-case 2030 scenario implies an enterprise value of roughly $8.3B if execution milestones are achieved.
- Recurring Revenue Model: Three defensible streams (hospital EHR, pharma RWE, solo practitioners) provide predictable growth
- Network Effects: All 8 diseases live by May 2027 = liquidity impossible for single-disease competitors to replicate
Projection Disclaimer: These figures are internal planning scenarios only, not guarantees of future performance, not an offer of securities, and not financial advice. They depend on execution, adoption, reimbursement, regulation, capital availability, dilution, competition, and broader market conditions. Any token-related upside is speculative and should not be relied upon. Do your own research (DYOR) and consult a licensed financial adviser before making investment decisions.
Why Operating Outcomes Matter:
- 20-30% reduction in ER visits → hospitals pay more for proven ROI
- 15-25% improvement in treatment adherence → pharma pays premium for outcomes data
- Earlier intervention = longer patient lifespans = longer platform engagement
- Tiered awards program ($100-$5K) creates patient evangelists who drive organic growth
Why Incentives Align: When patients track better, outcomes improve. When outcomes improve, hospitals and pharma pay more. When revenue grows, token value grows. When tokens appreciate, warrior awards grow. Everyone wins when patients win.
Pricing Structure
Patient and Caregiver App is completely free
- 116 languages
- No pop ups
- No ads
- No cross-selling
Provider access is simple, predictable pricing. No setup fees, no hidden costs. Same features at every tier-pricing scales with organization size.
- Full patient tracking access
- Treatment calendar sync
- Medication adherence
- Symptom logs & trends
- AI-powered alerts
- 109 languages
- Email support
Rural GPs, small clinics, independent physicians
- Everything in Solo
- Multi-provider dashboard
- Care team coordination
- Caregiver access
- Priority support
- Monthly reporting
- API access
Under 100 employees
- Everything in Small
- Custom reporting
- Advanced analytics
- Dedicated support
- Custom workflows
- Research data access
- Phone support
100-1,000 employees
- Everything in Medium
- White-label option
- Multi-site deployment
- Dedicated account manager
- 24/7 phone support
- Custom integrations
- SLA guarantees
Hospitals, oncology groups, health associations
Volume Pricing Example
A mid-sized oncology practice with 500 active cancer patients at the Enterprise tier ($15/month):
- Monthly cost: 500 patients × $15 = $7,500
- Annual cost: $90,000
- Cost per appointment: ~$3-4 (if patients visit quarterly)
ROI: Practices report 20-30% reduction in urgent care visits and 15-25% improvement in treatment adherence within 6 months, easily offsetting integration costs through better outcomes and reduced crisis management.
Revenue Architecture & 2030 Mix
CareHub™ generates revenue through three complementary streams: hospital/enterprise subscriptions ($15/patient/month), solo practitioner subscriptions ($5/patient/month), and pharma RWE data licensing (post-market surveillance).
Pricing Structure (Comparable to Industry Standards)
Our $1-15/patient/month pricing significantly undercuts established healthcare SaaS benchmarks:
- CMS RPM Reimbursement (CPT 99453-99458): $19-$61/patient/month for remote physiologic monitoring. Medicare pays providers $19.46 (setup) + $50.15/month (monitoring) + $41/month (interactive communication). Our $1-15 tier is 75%+ below provider cost.
- Chronic Care Management (CCM): CMS reimburses ~$62/patient/month (CPT 99490). Our integration reduces provider workload while improving outcomes.
- Cerner HealtheIntent: $5-$12/patient/month for chronic disease registries (enterprise pricing).
- Livongo (pre-Teladoc): $75/member/month for diabetes monitoring; we offer more comprehensive tracking at lower cost.
- Omada Health: $130-$350/participant for 16-week programs; our continuous model is more cost-effective long-term.
Sources: CMS 2024 Physician Fee Schedule, AAPC CPT Code Guidelines, Cerner/Oracle Health enterprise quotes, Livongo/Teladoc investor materials.
5-Year Revenue Projection (Conservative)
| Year | Disease Modules | EHR Patients | Solo Patients | Pharma RWE | Total ARR |
|---|---|---|---|---|---|
| 2026 | Cancer, Long COVID, Alzheimer's, Obesity+T2D | 90-150K* | ~5K | $1.2M | $9-15M |
| 2027 | All 8 diseases (full platform May '27) | 800K | 25K | $15M | $80-120M |
| 2028 | All 8 (scale + IPO) | 2.5M | 75K | $40M | $250-350M |
| 2029 | All 8 (post-IPO expansion) | 5M | 150K | $80M | $500-650M |
| 2030 | All 8 (mature, global) | 8M | 300K | $180M | $830M-$1B |
Conservative model: All 8 diseases live by May 2027. IPO target Q4 2027/Q1 2028 at $100M+ ARR. Enterprise @ $15/patient/month. Solo @ $5/patient/month. Pharma RWE scales with data volume. The solo-practitioner channel is modeled as a restrained floor, with upside driven mainly by stronger enterprise adoption.
Revenue Breakdown (2030)
- Hospital EHR Subscriptions: $672M (81%) - 7M patients × $8 × 12
- Pharma RWE Data Licensing: $150M (18%) - See detailed breakdown below
- Solo Practitioner Subscriptions: $15M (2%) - 250K patients × $5 × 12
Total: ~$830M ARR (conservative). The $15M solo-practitioner line is intentionally modeled as a floor, not the main global growth engine. Upside to $1.2B+ comes primarily from stronger enterprise adoption and major pharma exclusives.
Key Assumptions
- EHR-tracked patients: Subset of total app users whose providers have integrated CareHub
- Blended rate: $8/patient/month (mix of $3-5 Starter, $8-12 Professional, $15-20 Enterprise)
- Pharma revenue: Begins 2027 once patient data volume is sufficient for RWE insights
- Solo practitioner revenue: Conservative bottom-up channel that can later convert practices and small groups into larger provider-network or enterprise relationships
Scenario Forecasts & Growth Curves
5-Year Scenario Comparison: Conservative / Moderate / Aggressive
| Year | Conservative | Moderate | Aggressive | |||
|---|---|---|---|---|---|---|
| Patients | ARR | Patients | ARR | Patients | ARR | |
| 2026 | 120K | $10.8M | 168K | $15M | 240K | $22.8M |
| 2027 | 825K | $95M | 1.1M | $130M | 1.5M | $180M |
| 2028 (IPO) | 2.6M | $290M | 3.5M | $400M | 5M | $560M |
| 2029 | 5.2M | $580M | 7M | $780M | 10M | $1.1B |
| 2030 | 8.5M | $830M+ | 12M | $1.3B | 17M | $1.67B |
| Illustrative Valuation Range (10x ARR @ 2028) | $2.9B | $4B | $5.6B | |||
Scenario Assumptions:
- Conservative: 3-4 partners/market/year, 20% patient adoption, no exclusive network deals, $8 blended rate
- Moderate: 5-6 partners/market/year, 25% adoption, 1-2 large network partnerships, $9 blended rate
- Aggressive: 8+ partners/market/year, 30% adoption, US Oncology + major pharma exclusives, $10 blended rate
All 8 diseases live by May 2027. IPO target Q4 2027/Q1 2028 at $100M+ ARR threshold. All scenarios include: Hospital EHR licensing + Solo practitioner subscriptions + Pharma RWE data licensing.
Revenue Visualizations: Conservative vs Aggressive
Why We Model Conservatively
Healthcare enterprise sales are notoriously slow. Hospital IT committees, HIPAA compliance reviews, EHR integration testing, and physician adoption all create friction. We'd rather under-promise and over-deliver than chase aggressive numbers that require perfect execution.
- Conservative assumes: Normal enterprise sales cycles (6-9 months), no network-wide deals, organic patient adoption only
- Aggressive requires: US Oncology Network partnership ($10M+ single deal), major pharma RWE exclusives, accelerated global expansion
- Reality: We'll likely land somewhere in between-but investors should model on conservative with upside optionality
What Drives the 2x Difference?
| Factor | Conservative | Aggressive |
|---|---|---|
| EHR Patients (2030) | 7M | 15M |
| Hospital Partners/Market/Year | 2-3 | 6+ |
| Pharma RWE Revenue | $150M | $200M+ |
| US Oncology Network Deal | ❌ Not assumed | ✅ Network-wide |
| 2030 Total ARR | $830M+ | $1.67B |
A single US Oncology Network deal could move us from Conservative to Aggressive trajectory. That's the upside optionality-but we don't build our business plan around it.
2026 Market Entry Economics
*2026 Strategy: 1-2 Major Partners Per Market
Conservative Year 1: Land 1-2 strategic partnerships per market (not all 12). Focus on Arizona pilot (founder credibility), expand to North America (CUSMA/USMCA markets), then UK/Australia (Commonwealth systems, similar healthcare gaps, private providers avoid complex NHS/public procurement).
Target Partners by Market (2026)
| Health System | Cancer Patients | 20% Adoption | EHR |
|---|---|---|---|
| ARIZONA (Primary Market) - Land 1-2 of 4 | |||
| Mayo Clinic Arizona Scottsdale/Phoenix. #1 Hospital in AZ for 13 consecutive years. $17B+ system revenue. |
~50K | 6K | Epic |
| Banner Health / MD Anderson Largest nonprofit in AZ. 33 hospitals. 55K employees. $14B+ revenue. Cerner flagship. |
~80K | 9.6K | Cerner |
| HonorHealth / Virginia G. Piper 9 hospitals. Serves 5M in Phoenix metro. International clinical trial reputation. |
~40K | 4.8K | Epic |
| US Oncology Network Nation's largest community oncology network. 1,400+ physicians. 470+ locations. McKesson-backed. Arizona Oncology = pilot entry point. |
~1.5M | 180K | iKnowMed |
| NORTH AMERICA (CUSMA/USMCA) - Land 1 of 2 | |||
| Princess Margaret Cancer Centre 🇨🇦 Toronto. Part of UHN ($17B+ system). World #3 hospital (Newsweek 2024). Canada's #1 research hospital. 220 oncology beds. |
~55K | 6.6K | Epic |
| TecSalud / Hospital San José 🇲🇽 Monterrey. Tec de Monterrey medical system. MD Anderson & Houston Methodist partnerships. Research hospital network. |
~25K | 3K | Epic |
| UK (Private Providers) - Land 1 of 3 | |||
| Spire Healthcare (Oncology) 🇬🇧 UK's #2 private healthcare provider. 38 hospitals, £1.5B revenue. Established cancer centres in GenesisCare partnership. |
~30K | 3.6K | Various |
| The Christie NHS / Private 🇬🇧 Manchester. Europe's largest single-site cancer centre. 60K+ patients/year. UK's first proton beam therapy. HCA Private partnership. |
~60K | 7.2K | NHS Spine |
| Ramsay Health Care UK 🇬🇧 22 private hospitals, 9 treatment centres. Part of $12B global system. Strong oncology & rehabilitation services. |
~25K | 3K | Various |
| AUSTRALIA - Land 1 of 3 | |||
| Peter MacCallum Cancer Centre 🇦🇺 Melbourne. Australia's only dedicated public cancer hospital. #14 worldwide (Newsweek 2024). $1B purpose-built facility. |
~45K | 5.4K | Epic |
| Ramsay Australia (Oncology) 🇦🇺 Australia's largest private hospital operator. 70+ facilities. Dedicated cancer hospitals: Border, Western Sydney Oncology. |
~40K | 4.8K | Various |
| Chris O'Brien Lifehouse 🇦🇺 Sydney. Australia's first comprehensive cancer centre. Integrated research + treatment. Private/public partnership model. |
~25K | 3K | Epic |
| If All 12 Land (Best Case) | ~2M | 237K | |
Conservative Year 1 Scenarios
| Scenario | Partners | Patients (20%) | ARR |
|---|---|---|---|
| Conservative: AZ only (Mayo + Banner) | 1-2 | 16K | $1.5M |
| Moderate: AZ + Princess Margaret | 2-3 | 27K | $2.6M |
| Stretch: AZ + CA/MX + 1 UK + 1 AU | 4 | 43K | $4.1M |
| Moonshot: US Oncology Network-wide | 1 (network) | 180K | $17.4M |
Calculation: patients × $8/month blended rate × 12 months. US Oncology Network is a separate deal that could transform Year 1.
Why Arizona? Why UK & Australia?
Our founder is a terminal cancer patient who has been treated by all three Arizona target systems. His experience exposes exactly the care gaps CareHub™ solves:
- 1,000 pages of medical records at HonorHealth reduced to 10 pages when transferred to Banner Health. Tracking down records takes weeks. Patients deserve portable data.
- Social worker role eliminated at Arizona Oncology as cost-cutting. Patients received a list of 100 phone numbers with no active links. Useless for a homeless patient without internet.
- Ignored symptom warnings led to hospitalization with fractured vertebrae, ribs, and sternum. Given 72 hours to live. Earlier intervention would have prevented crisis.
- Drug side effects unreported: Severe Zometa reaction (102° fever, migraine) noted but treatment continued. Now permanent jawbone damage.
- Insurance gaps forced sale of mortgage-free home, assets at 30-40 cents on the dollar. Two years homeless in Arizona desert.
Why UK & Australia? 🇬🇧 🇦🇺
Our founder grew up in the UK and lived in Australia. Same problems, different healthcare systems. The Commonwealth gap:
- NHS waiting lists push cancer patients to private providers-but private/public data doesn't flow. Patients fall between systems.
- Australia's Medicare + private insurance split creates the same data silos. Peter Mac to Ramsay = fax and phone calls.
- Private oncology providers (Spire, Ramsay, Christie Private) have simpler procurement than NHS trusts-faster pilots, clearer ROI conversations.
Solo Practitioner Expansion Model
Solo Practitioner Revenue Floor
Patient-driven demand creates a bottom-up channel to complement enterprise sales. Cancer patients discover CareHub™ through social media, word-of-mouth, and caregiver networks, then ask their oncologists to integrate. This section is intentionally modeled as a conservative floor rather than the primary global growth engine.
Pricing: Solo Practitioner Tier
- Setup: Free onboarding (vs $10K-$50K enterprise)
- Per-patient fee: $5/month (vs $8 enterprise blended)
- Maximum patients: 500/practice (upgrade to enterprise after)
- Features: Full symptom tracking, medication logs, alerts-no EHR integration required
Conservative Floor: ~100 Solo Practitioners Per Market/Year
| Year | Markets | Solo Practitioners | Avg Patients/Practice | Total Patients | ARR @ $5/mo |
|---|---|---|---|---|---|
| 2026 | 3 (pilot) | 30 | 24 | 1,200 | $72K |
| 2027 | 10 | 250 | 40 | 10,000 | $600K |
| 2028 | 15 | 750 | 40 | 30,000 | $1.8M |
| 2029 | 25 | 2,500 | 40 | 100,000 | $6M |
| 2030 | 35 | 6,250 | 40 | 250,000 | $15M |
Conservative floor: ~100 practitioners per market per year. Patient counts stay lower than enterprise because there is no EHR integration, and many of these practices should convert into larger provider-network or enterprise relationships over time. That is why the $15M 2030 number is treated as a floor rather than the total global solo-practice opportunity.
Pharma RWE Licensing Model
Pharma RWE Data Licensing: The $200M Opportunity
Why pharma will pay: Clinical trials test drugs on ~3,000-5,000 patients in controlled settings. Real-world evidence from millions of patients in actual clinical practice is exponentially more valuable for:
- Post-market surveillance: FDA requires safety monitoring; RWE catches rare adverse events
- Label expansion: Prove efficacy in populations excluded from trials (elderly, comorbidities)
- Comparative effectiveness: Head-to-head vs competitors in real practice
- Payer negotiations: Demonstrate value to justify pricing
- New drug development: Identify unmet needs, patient journeys, treatment patterns
Comparable Pricing (Cited)
| Company | Model | Pricing | Source |
|---|---|---|---|
| Flatiron Health | Oncology RWE (2.8M patients) | $2-5M/pharma/year | Roche acquisition docs 2018; industry estimates |
| IQVIA | Claims + EHR data | $1-10M/study | IQVIA investor presentations |
| Tempus | Genomic + clinical data | $500K-3M/partnership | Tempus partnerships (AstraZeneca, GSK) |
| Veeva | Patient data platform | $100K-1M/client/year | Veeva Crossix pricing |
| Roche/Flatiron Acquisition | Company valuation | $1.9B for 2.8M patients | Roche press release Feb 2018 |
CareHub™ Pharma Pricing Model
| Tier | Access Level | Annual Fee | Includes |
|---|---|---|---|
| Standard | Aggregated insights, quarterly reports | $500K | Treatment patterns, adherence trends, symptom profiles (de-identified) |
| Professional | Custom queries, comparative effectiveness | $1.5M | + Drug-specific cohort analysis, outcomes data, API access |
| Enterprise | Full dataset access, custom studies | $3-5M | + Prospective data collection, FDA-ready outputs, dedicated support |
| Exclusive | Therapeutic area exclusivity (1-2 years) | $10-20M | First-look rights, co-development of endpoints, joint publications |
Pharma Revenue Trajectory
| Year | Patients | Pharma Clients | Avg Contract | RWE Revenue |
|---|---|---|---|---|
| 2026 | 24-48K | 0 | - | $0 (insufficient data) |
| 2027 | 250K | 2-3 | $1M | $3M |
| 2028 | 1M | 8-10 | $1.5M | $15M |
| 2029 | 3M | 20-25 | $2M | $50M |
| 2030 | 7M | 40-50 | $3M | $150M |
Assumptions: Top 20 pharma spend $40B+/year on RWE (Deloitte 2024). With 7M+ patients across 8 disease/condition states, CareHub™ captures ~0.4% of market. One exclusive deal ($15-20M) could accelerate this significantly.
Why CareHub™ Data Is Uniquely Valuable
- Continuous, patient-reported data: Daily symptom logs, medication timing, side effect severity
- Real-time adherence: Actual pill-taking behavior, not refill proxies
- Outcome correlation: Link behaviors → symptoms → outcomes in ways claims can't
- Multi-disease crossover: Cancer patient with diabetes + long COVID = rare longitudinal view
- International coverage: Same platform across US, UK, Australia, Canada, Mexico = regulatory arbitrage for multi-country studies
Detailed revenue model breakdown: the revenue architecture, scenario modeling, 2026 market entry, solo practitioner expansion, and pharma RWE licensing sections above now hold the extracted financials.
Sales Channels & Market Penetration
CareHub™ reaches healthcare providers through two complementary channels:
1. Direct Enterprise Sales (Primary)
Traditional B2B sales targeting:
- Integrated delivery networks (Epic, Cerner customers)
- Academic medical centers
- Large oncology practices
- Diabetes management clinics
2. Cultural Ambassadors (Underserved Markets)
9 Strategic Cultural Ambassadors across 4 continents open doors in markets where traditional B2B sales cannot reach:
- Facilitate introductions to local healthcare systems
- Bridge trust gaps in underserved communities
- Onboard patients who drive provider demand
Target: 110+ enterprise partnerships in underserved markets by 2030
Note: Ambassador-facilitated revenue is included in Hospital EHR Subscriptions and is not a separate revenue stream.
Citations & Sources
Healthcare SaaS Pricing Benchmarks
- CMS RPM Reimbursement (2024): CPT 99453 ($19.46 setup), 99454 ($50.15/mo monitoring), 99457 ($41.17/mo interactive) - CMS Physician Fee Schedule 2024
- Chronic Care Management: CPT 99490 ($62/patient/month) - CMS Medicare Physician Fee Schedule
- Cerner HealtheIntent: $5-$12/patient/month for chronic disease registries - Oracle Health enterprise pricing (2024)
- Livongo (pre-Teladoc): $75/member/month diabetes monitoring - Teladoc investor relations, Livongo acquisition docs 2020
- Omada Health: $130-$350/participant 16-week program - Omada enterprise pricing 2024
Pharma RWE Market & Pricing
- Global RWE market: $2.44B (2024), 16.5% CAGR to $5.2B by 2030 - Mordor Intelligence 2025
- Pharma RWE spend: $40B+/year across top 20 pharma - Deloitte "Real-World Evidence: From Activity to Impact" 2024
- Flatiron Health acquisition: $1.9B for 2.8M patient oncology database - Roche press release, Feb 14, 2018
- Flatiron licensing: $2-5M/pharma client/year - Industry analyst estimates, SEC filings
- IQVIA RWE studies: $1-10M per study - IQVIA investor presentations 2023-24
- Tempus partnerships: $500K-3M per partnership - AstraZeneca, GSK partnership announcements
Healthcare Operations
- Patient portal adoption: 62% average at integrated delivery networks - Epic Systems 2024 Annual Report
- RPM outcomes: 20-30% reduction in readmissions - JAMA Network Open 2023
- EHR market share: Epic 36%, Oracle Health/Cerner 25%, Meditech 12% - KLAS Research 2024
- Cultural Ambassador model: CDC Healthy Tribes Community Health Worker program outcomes
Partner Research
- US Oncology Network: 1,400+ physicians, 470+ sites, 1.5M patients/year - McKesson/US Oncology corporate materials 2024
- Mayo Clinic system: $17B+ revenue - Mayo Clinic Annual Report 2023
- Banner Health: 33 hospitals, $14B+ revenue - Banner Health corporate materials 2024
- Princess Margaret: World #3 hospital - Newsweek World's Best Hospitals 2024
- Peter MacCallum: #14 worldwide cancer centre - Newsweek World's Best Specialized Hospitals 2024